The effects of inhaled steroid and theophylline on systemic inflammation in COPD

European Journal of Inflammation

Volumn 9, Issue 3, 2011, Pages 241-248

  Boyacý, Habim ^a   Pala, A ^b   Argun Baris S ^c   Basyigit, I ^a   Yildiz, F ^a   Ilgazli, A ^a  

^a KOCAELI UNIVERSITY   (Turkey)

^b Nigde State Hospital Eye Clinic   (Turkey)

^c Department of Pulmonary Disease   (Turkey)

Author keywords

Anti inflammatory treatment; COPD; Systemic inflammation

Indexed keywords

BRONCHODILATING AGENT; C REACTIVE PROTEIN; CORTICOSTEROID; FLUTICASONE PROPIONATE; INTERLEUKIN 6; THEOPHYLLINE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; AIRWAY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CORTICOSTEROID THERAPY; CYTOKINE RELEASE; DISEASE SEVERITY; DRUG EFFECT; FORCED EXPIRATORY VOLUME; HUMAN; IMMUNE RESPONSE; INFLAMMATION; LABORATORY TEST; LUNG FUNCTION TEST; SPIROMETRY; TREATMENT OUTCOME;

EID: 84858686913     PISSN: 1721727X     EISSN: None     Source Type: Journal    
DOI: 10.1177/1721727x1100900304     Document Type: Article

References (28)

1. Global Initiative for Chronic Obstructive Pulmonary Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. Report, 2007.
2. National Heart, Lung and Blood Institute. Morbidity & mortality: chart book on cardiovascular, lung and blood diseases. Bethesda, MD: US Department of Health and Human Services, Public Health Service, National Institutes of Health; 1998. Available from: URL:www.nhlbi.nig.gov/nhlbi/seiin/ other/cht-book/htm.
3. Hogg JC. Pathophysiology of airflow limitation in chronic obstructive pulmonary disease. Lancet 2004; 364:709-21. (Pubitemid 39140629)
4. Schols AM, Buurman WA, Staal van den Brekel AJ, Dentener MA, Wouters EF. Evidence for a relation between metabolic derangements and increased levels of inflammatory mediators in a subgroup of patients with chronic obstructive pulmonary disease. Thorax 1996; 51:819-24.
5. Agusti A. Systemic effects of chronic obstructive pulmonary disease: what we know and what we don't know (but should). Proceedings of the American Thoracic Society 2007; 4(7):522-25. (Pubitemid 47547846)
6. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Yates JC, Vestbo J. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356:775-89. (Pubitemid 46294610)
7. Man SF, Sin DD. Effects of corticosteroids on systemic inflammation in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2005; 2: 78-82. (Pubitemid 40562967)
8. Sin DD, Lacy P York E, Man SF. Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004; 170(7):760-65. (Pubitemid 39298991)
9. Barnes PJ. Theophylline in chronic obstructive pulmonary disease: new horizons. Proc Am Thorac Soc 2005; 2(4):334-39. (Pubitemid 41699692)
10. American Thoracic Society Statement. Standardization of spirometry, 1994 update. Am J Respir Crit Care Med 1995; 152:1107-13.
11. Gan WQ, Man SFP, Senthilselvan A, Sin DD. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and meta-analysis. Thorax 2004; 59:574-80. (Pubitemid 38901515)
12. Pinto-Plata VM, Mullerova H, Toso JF, Feudjo- Tepie M, Soriano JB, Vessey RS, Celli BR. C- reactive protein in patients with COPD, control smokers and nonsmokers. Thoraks 2006; 61(1):23-28.
13. Karadao F, Kirdar S, Karul A, Ceylan E. The value of C-reactive protein as a marker of systemic inflammation in stable chronic obstructive pulmonary disease. Eur J Int Med 2008; 19:104-8.
14. Dev D, Wallace E, Sankaran R, Cunniffe J, Govan JR, Wathen CG, Emmanuel FX. Value of C-reactive protein measurements in exacerbations of chronic obstructive pulmonary disease. Respir Med 1998; 92:664-67. (Pubitemid 28174838)
15. Hurst JR, Donaldson GC, Perera WR, Wilkinson TM, Bilello JA, Hagan GW, Vessey RS, Wedzicha JA. Use of plasma biomarkers at exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006; 174:867-74. (Pubitemid 44564786)
16. Gan WQ, Paul Man SF, Sin DD. The interactions between cigarette smoking and reduced lung function on systemic inflammation. Chest 2005; 127:558-64. (Pubitemid 40229317)
17. Wu SJ, Chen P, Jiang XN, Liu ZG. C-reactive protein level and the correlation between lung function and CRP levels in patients with chronic obstructive pulmonary diseases. Zhong Nan Da Xue Xue Bao Yi Xue Ban 2005; 30(4):444-46. (Pubitemid 41375148)
18. Sin DD, Man SF. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation 2003; 107:1514-19. (Pubitemid 36378490)
19. Mannino DM, Ford ES, Redd SC. Obstructive and restrictive lung disease and markers of inflammation. Am J Med 2003; 114:758-62.
20. Dentener MA, Creutzberg EC, Schols AM, Mantovani A, van't Veer C, Burman WA, Wouters EF. Systemic anti-inflammatory mediators in COPD: increase in soluble interleukin 1 receptor II during treatment of exacerbations. Thorax 2001; 56:721-26. (Pubitemid 32831700)
21. Keatings VM, Collins PD, Scott DM, Barnes PJ. Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med 1996; 153(2):530-34.
22. De Godoy I, Donahoe M, Calhoun WJ, Mancino J, Rogers RM. Elevated TNF- alpha production by peripheral blood monocytes of weight-losing COPD patients. Am J Respir Crit Care Med 1996; 153(2):633-37.
23. Vernooy JH, Kucukaycan M, Jacobs JA, Chavannes NH, Burman WA, Dentener MA, Wouters EF. Local and systemic inflammation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002; 166:1218-24.
24. Donaldson GC, Terence A, Seemungal R, Irem S. Airway and systemic inflammation and decline in lung function in patients with COPD. Chest 2005; 128:1995-2004. (Pubitemid 41507533)
25. Basyigit I, Yildiz F, Ozkara SK, Yildirim E, Boyaci H, Ilgazli A. Addition of inhaled corticosteroid on combined bronchodilator therapy in patients with COPD. Pulm Pharmacol Ther 2005; 18:422-26. (Pubitemid 41354268)
26. Keatings VM, Jatakanon A, Wordsell YM, Barnes PJ. Effects of oral and inhaled corticosteroid on inflammatory indices in asthma and COPD. Am J Respir Crit Care Med 1997; 155:542-48. (Pubitemid 27085799)
27. Sin DD, Man SF, Marciniuk DD, et al.: ABC (Advair, Biomarkers in COPD) Investigators. The effects of fluticasone with or without salmeterol on systemic biomarkers of inflammation in COPD. Am J Respir Crit Care Med 2008; 177(11):1207-14. (Pubitemid 351860929)
28. Iiboshi H, Ashitani J, Katoh S, Sano A, Matsumoto N, Mukae H, Nakazato M. Long term treatment with theophylline reduces neutrophils, interleukin-8 and tumor necrosis factor-alpha in the sputum of patients with chronic obstructive pulmonary disease. Pulm Pharmacol Ther 2007; 20(1):46-51. (Pubitemid 44648800)